Myriad Genetics (MYGN) Cost of Revenue (2009 - 2026)

Myriad Genetics (MYGN) has reported Cost of Revenue for 18 consecutive years, with $62.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cost of Revenue rose 1.78% year-over-year to $62.8 million; the TTM figure through Mar 2026 stood at $249.0 million (changed 0.12% YoY), while the FY2025 annual figure was $247.9 million, down 1.7% from the prior year.
• Cost of Revenue was little changed at $62.8 million in Q1 2026 per MYGN's latest filing, from $63.0 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $64.6 million in Q1 2024 and bottomed at $48.0 million in Q1 2022.
• Historically, Cost of Revenue has averaged $58.9 million across 5 years, with a median of $61.3 million in 2025.
• Annual changes were most pronounced in 2022 — Cost of Revenue surged 771.93% — and 2025, when it declined 4.81%.
• Myriad Genetics' Cost of Revenue stood at $53.9 million in 2022, then increased by 14.29% to $61.6 million in 2023, then decreased by 3.08% to $59.7 million in 2024, then advanced by 5.53% to $63.0 million in 2025, then decreased by 0.32% to $62.8 million in 2026.
• Business Quant data shows MYGN's Cost of Revenue at $62.8 million in Q1 2026, $63.0 million in Q4 2025, and $61.9 million in Q3 2025.